May 3, 2012
Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos´s Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks

April 24, 2012
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012

February 4, 2012
Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)

February 1-4, 2012
ASCO GU 2012

February 13-14, 2012
The 14th Annual BIO CEO & Investor Conference

June 1-5, 2012
ASCO 2012 Annual Meeting